Every quarter, many money managers have to disclose what they've bought and sold, via "13F" filings. Their latest moves can shine a bright light on smart stock picks.
Today, let's look at Fisher Asset Management, founded in 1979 by Ken Fisher. You may know Fisher by his longtime column in Forbes magazine, where he's also No. 271�in the magazine's list of the 400 richest Americans, with a net worth of $1.9 billion. You may know his father as well: Phil Fisher wrote the seminal investing text, Common Stocks, Uncommon Profits.
The company's reportable stock portfolio totaled $36.4 billion�in value as of March 31, 2013. It manages money for more than 100 �large institutions, and its strategy involves macroeconomic research and fundamental analysis.
Interesting developments
So what does Fisher's latest quarterly 13F filing tell us? Here are a few interesting details:
The biggest new holdings are Coinstar�and Vishay Intertechnology. Other new holdings of interest include the railroad company CSX (NYSE: CSX ) , which operates more than 21,000 miles of track and is yielding 2.3%. It has been hurt by softness in demand for coal (in part due to low natural gas prices), but coal is likely to remain in demand internationally, and coal exports have been increasing. CSX is geographically well positioned to benefit from such exports, with its access to Eastern and Gulf Coast ports. Its first quarter reflected growth in revenue and earnings.
Top 10 International Companies To Invest In Right Now: Vermillion Inc.(VRML)
Vermillion, Inc., together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostics tests that help physicians to diagnose, treat, and improve outcomes for patients. It develops diagnostic tests in the fields of oncology, hematology, cardiology, and women?s health with the initial focus on ovarian cancer. The company?s lead product includes OVA1, an ovarian tumor triage test that enables pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. It is also developing various programs in other clinical aspects of ovarian cancer, as well as in peripheral arterial disease. The company has strategic alliance agreement with Quest Diagnostics Incorporated; and collaborations with various academic and research institutions to develop and commercialize diagnostic tests. It serves clinical reference laboratories, hospital laboratories, and physician offices. The company was formerly known as Ciphergen B iosystems, Inc. and changed its name to Vermillion, Inc. in August 2007. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.
Advisors' Opinion:- [By Bryan Murphy]
It's not an uncommon situation. While investors are scouring the news (or lack thereof) from a company, they're not paying much attention to the stock itself. Big mistake, as stocks can and do have a life of their own, sometimes independently of the company. Vermillion, Inc. (NASDAQ:VRML) is the most recent example of this alarming disconnect. While news from the company of late has been fairly benign and a little non-existent, shares of VRML has been inching towards a key technical line in the sand that if crossed under could spark a fairly rapid selloff.
Top 5 Railroad Stocks To Buy Right Now: A-Cap Resources Ltd (ACB)
A-Cap Resources Limited is an Australia-based mineral exploration company. The Company�� principal activity during the fiscal year ended June 30, 2012 (fiscal 2012), is exploration of its tenement portfolio in Botswana and the ongoing feasibility studies into the Letlhakane Uranium Project. The Company focuses on investment in Botswana in Southern Africa, where it holds over 5000 square kilometer of exploration licenses. The Company�� projects include Botswana project, Letlhakane project, Mea-Coal project, Bolau-Coal project and Southern Pans project. The Company�� 100% owned Letlhakane Uranium Project is located in northeast Botswana. In July 2012, A-Cap announced the discovery of two new coal projects in Botswana, transforming the Company into a multi-commodity exploration outfit. Advisors' Opinion:- [By John Heinzl]
You'll notice that these numbers don't add up to $1.4988. That's because the 2012 distribution also contained a hefty chunk of return of capital (70.489 cents). ROC isn't taxable immediately; rather, it is subtracted from the adjusted cost base (ACB) of the units, which gives rise to a larger capital gain, or smaller capital loss, when the units are ultimately sold. Many REITs and mutual funds also distribute ROC. ROC can be a bit of a headache for investors. If you hold BIP in a non-registered account, you (or your accountant), will need to track those ROC payments in order to keep your ACB up to date. Knowing the ACB is necessary to calculate your capital gain, or loss, when it comes time to sell.
Top 5 Railroad Stocks To Buy Right Now: Neogenomics Inc (NEO)
NeoGenomics, Inc. (NeoGenomics) operates a network of cancer-focused testing laboratories. The Company offers testing services, including Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations; immunohistochemistry (IHC) testing, this is the process of identifying cell proteins in a tissue section utilizing the principle of antibodies binding specifically to antigens, and molecular testing, which is a cancer diagnostic tool focusing on the analysis of DNA and ribonucleic acid (RNA), as well as the structure and function of genes at a molecular level.
The cancer testing services, that the Company offers to community-based pathologists are designed to be a natural extension of, and complementary to, the services that they perform within their own practices. In areas where the Company does not provide services to community-based pathology practices, it may directly serve oncology, dermatology, urology and other clinician practices that prefer to have a direct relationship with a laboratory for cancer-related genetic and molecular testing services. NeoGenomics services these types of clients with a global service offering where it performs both the technical and professional components of the tests ordered.
The Company offers tech-only flow cytometry and immunohistochemistry testing services. These types of testing services generally allow the professional interpretation component of a test to be billed separately from the technical component. Its NeoFISH, NeoFLOW and other tech-only service offerings allow properly trained and credentialed community-based pathologists to extend their own practices by performing ! professional interpretations services.
The Company's tech-only services are designed to give pathologists the option to choose, on a case by case basis, whether they want to order just the technical information and images relating to a specific test so they can perform the professional interpretation, or order global services and receive a test report, which includes a NeoGenomics Pathologist�� interpretation of the test results.
The Company also offers a set of global services to meet the needs of those clients who are not credentialed and trained in interpreting genetic tests and who are looking for specialists to interpret the testing results for them. In its global service offerings, its lab performs the technical component of the tests and its doctor of medicine (M.D.s) and doctor of philosophy (Ph.D) s to provide the interpretation services. Its genetic pathology solutions (GPS) report summarizes all relevant case data from its global services on one summary report.
The Company competes with General Electric Healthcare Services and Novartis, A.G.
Advisors' Opinion:- [By John Udovich]
One way or the other, Merrimack Pharmaceuticals Inc (NASDAQ: MACK), Covidien plc (NYSE: COV), NeoGenomics, Inc (NASDAQ: NEO) and�CollabRx Inc (NASDAQ: CLRX) are targeting Barrett's Esophagus�or�esophageal cancer�(the former often leads to the latter) ��a form of cancer that may not be on the top of your list of cancers but is nevertheless on the rise. Approximately 3 million Americans suffer from Barrett's Esophagus, �a condition that�develops as a result of chronic injury from gastroesophageal reflux disease (GERD) where the�normal esophageal lining is replaced with abnormal cells (known as Barrett�� tissue), putting patients at greater risk of developing cancer of the esophagus. And although less than 1% of these patients develop cancer each year, esophageal carcinoma is frequently not detected until later stages, at which point therapy options are limited, extremely invasive, and often ineffective.�This means that�early detection is important�along with�regular surveillance is recommended.�
Top 5 Railroad Stocks To Buy Right Now: The Cheesecake Factory Incorporated(CAKE)
The Cheesecake Factory Incorporated operates upscale, casual, full-service dining restaurants in the United States. As of February 23, 2012, the company operated 170 dining restaurants, including 156 restaurants under The Cheesecake Factory mark in 35 states and the District of Columbia; 13 restaurants under the Grand Lux Cafe mark in 9 states; and 1 restaurant under the RockSugar Pan Asian Kitchen mark in California. It also owns and operates two bakery production facilities located in Calabasas Hills, California; and Rocky Mount, North Carolina. The company produces baked desserts and other products for its restaurants, as well as sells cheesecakes and other baked products on a wholesale basis to other foodservice operators, retailers, and distributors. The Cheesecake Factory Incorporated was founded in 1972 and is based in Calabasas Hills, California.
Advisors' Opinion:- [By John Dessauer]
Cheesecake Factory (CAKE) is a financially strong company that is committed to share buybacks. Cheesecake Factory bought back 2.1 million shares at a cost of $90.2 million in the third quarter.
- [By Jayson Derrick]
Analysts at JPMorgan maintained a Neutral rating on The Cheesecake Factory (NASDAQ: CAKE) with a price target lowered to $47 from a previous $50. Shares lost 1.38 percent, closing at $42.88.
- [By Rick Aristotle Munarriz]
Alamy McDonald's (MCD) has been struggling to heat up its sales for more than a year, but let's not assume that all fast food chains are in the same boat. In fact, as McDonald's tries to upgrade its menu with premium-priced items and update its eateries with fancy decor, free Wi-Fi, and barista-brewed coffee beverages, a much smaller rival is doing just fine with a throwback business model and menu. At a time when many of its more modern peers are struggling to ring up sales, Sonic (SONC) -- the chain of drive-in restaurants where some orders are still delivered to parked cars by carhops on roller skates -- is doing just fine. Retro Chic Sonic reported another solid quarter on Monday. Same-restaurant sales rose 2.2 percent for its fiscal quarter ending in November. Margins improved to the point where adjusted earnings per share climbed 18 percent with the help of an aggressive share buyback plan. McDonald's doesn't operate on the same fiscal calendar, but we know that same-restaurant sales in the U.S. declined 0.8 percent in November and were up a mere 0.2 percent in October. McDonald's is the world's largest burger chain, but it's had several months since Oct. 2012 where it failed to drum up more sales than it did a year earlier. Meanwhile, Sonic is on a roll. This isn't a fluke. Sonic posted a 5.9 percent surge in same-restaurant sales during its summer quarter. Zigging When McDonald's Zags Sonic and McDonald's both serve cheap burgers, but what's more interesting to consider is where the two companies are going in different directions. McDonald's has been on a health kick lately. It's been promoting its grilled chicken salads and recently added breakfast sandwiches made with egg whites. Sonic, on the other hand, is crediting no small part of the success of its most recent quarter to its milkshakes and new Cheesecake Bites. Consumers may talk about eating healthier, but they do something else when they're eating out. We're seeing this in the chain
No comments:
Post a Comment